CLINICAL TRIAL SERVICES


SEEK SOLUTION TO YOUR CLINICAL TRIALS

At SNAC, we offer a full suite of regulatory-compliant imaging-related services tailored to meet your clinical trial needs. With particular focus on MS clinical trials, our central MRI reading service is your solution to investigating the efficacy of disease modifying therapies.

ENGAGE WITH OUR EXPERTS

SNAC offers a unique combination of in-house expertise in neuroscience, imaging science, clinical trials, neurology and radiology. Closely affiliated and co-located with the MS Clinic and MS Clinical Trials Unit at the Brain and Mind Centre in Sydney, Australia, we have unparalleled insights into the requirements of individual study sites, clinical practice and research needs.

ADHERENCE TO REGULATORY COMPLIANCE

At SNAC, we offer a full suite of regulatory-compliant imaging-related services tailored to meet your clinical trial needs. With particular focus on MS clinical trials, our central MRI reading service is your solution to investigating the efficacy of disease modifying therapies.


ENSURE THE SUCCESS OF YOUR CLINICAL TRIALS USING OUR CENTRAL READING SERVICES







THE SNAC TOOLBOX- APPROACHES FOR STANDARD AND CUSTOMISED OUTCOME MEASURES AND REMYELINATION CLINICAL TRIALS


SNAC offers a standardised battery of lesion activity and brain atrophy outcome measures, and customised solutions for studies utilising advanced imaging techniques such as diffusion imaging and magnetisation transfer imaging. We have also developed a tailored, multimodal central reading solution for Phase 2 clinical trials of emerging remyelinating therapies, which incorporates regulatory-compliant central reading for MRI, multifocal visual evoked potential (mfVEP), optical coherence tomography (OCT), and low contrast visual acuity (LCVA). ​










Advanced Imaging Techniques and Analysis​

Delineating the degree of tissue injury and microstructural changes in MS lesions and surrounding white matter ​

Understanding MS pathophysiology using conventional MRI approaches (e.g. fluid-attenuated inversion recovery (FLAIR), T1-weighted imaging) has its limitations. Such methods are unable to differentiate between the many pathologies that lesions exhibit, e.g. demyelination, inflammation, gliosis. Increased specificity and sensitivity in assessing the underlying MS pathology can be gained through advanced MRI approaches that SNAC routinely employs. This includes diffusion MRI and magnetisation transfer imaging permitting valuable insight into the microstructural changes within lesions and of the “normal appearing” white matter surrounding such lesions.







A Multimodal Turnkey Central Reading Solution for Phase 2 Remyelination Clinical Trials​


SNAC is redefining Phase 2 clinical trials of emerging remyelinating therapies for MS. We offer a unique, multimodal approach to testing remyelination in both acute and chronic MS lesions. Our remyelination biomarker platform has been validated with both clinical research and Phase 2 clinical trials. Here, we utilise the visual system as a platform to provide accurate measures of remyelination. This method is proven to be reliable, as the visual pathways are:

  • Highly susceptible to damage in MS
  • Accessible to in-vivo structural and functional measurements, including Multifocal Visual Evoked Potential (mfVEP), Magnetic Resonance Imaging (MRI), Optical Coherence Tomography (OCT), and Low Contrast Visual Acuity (LCVA).







  • OTHER SERVICES​


    OTHER DISEASES

    SNAC also provides central MRI and CT reading for clinical trials involving other neurological diseases. This includes dedicated services for cerebrovascular and neurodegenerative disease treatment clinical trials.

    COLLABORATE WITH US

    SNAC also provides central MRI reading for independent and collaborative clinical research and Investigator Initiated Studies, including studies involving predictive modelling of patient outcomes and extended monitoring of existing therapies. The results of these studies support improved understanding of drug effects and their applications, enhanced clinical practice and patient care. At SNAC, we offer a full suite of regulatory-compliant imaging-related services tailored to meet your clinical trial needs. With particular focus on MS clinical trials, our central MRI reading service is your solution to investigating the efficacy of disease modifying therapies.